Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 3, 1998, Pages 332-341

  Neuvonen, Pertti J ^a   Kantola, Teemu ^a   Kivistö, Kari T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYITRACONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; PRAVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOXICITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; VOLUNTEER;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITRACONAZOLE; MALE; MIXED FUNCTION OXYGENASES; PRAVASTATIN; SIMVASTATIN;

EID: 0031892901     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90165-5     Document Type: Article

References (27)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
3. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin [letter]. N Engl J Med 1988;318:46-7.
4. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter]. N Engl J Med 1995;333:664-5.
5. Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996;11:1846-7.
6. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals [letter]. Arch Dermatol 1996;132: 1254.
7. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
8. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32: 210-58.
9. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin; IV: identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-61.
10. Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18:476-83.
11. Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997;53:299-336.
12. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993;65:410-3.
13. Kliem V, Wanner C, Eisenhauer T, Olbricht CJ, Doll R, Boddaert M, et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc 1996;28:3126-8.
14. Stubbs RJ, Schwartz M, Bayne WF. Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. J Chromatogr 1986;383:438-43.
15. Morris MJ, Gilbert JD, Hsieh JY, Matuszewski BK, Ramjit HG, Bayne WF. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Biol Mass Spectrom 1993;22:1-8.
16. Funke PT, Ivashkiv E, Arnold ME, Cohen AI. Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom 1989; 18:904-9.
17. Manning JA, Swanson BN, Emaus NA, Fry J. A semi-automatic, radioenzymatic assay for pravastatin and lovastatin in human serum [abstract]. Pharm Res 1984;6:237.
18. Pentikäinen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992;32:136-40.
19. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 1990;532:203-6.
20. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138-45.
21. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4: 247-59.
22. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Munzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996;42:387-9.
23. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990;29:239-43.
24. Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Takahagi H, et al. Biotransformation of pravastatin sodium; I: mechanism of enzymic transformation of epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993;192:597-602.
25. Muramatsu S, Miyaguchi K, Iwabuchi H, Matsushita Y, Nakamura T, Kinoshita T, et al. Metabolism of pravastatin sodium in isolated rat hepatocytes. Xenobiotica 1992;22:487-98.
26. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15.
27. Agbin NE, Brater DC, Hall SD. Interaction of diltiazem with lovastatin and pravastatin [abstract]. Clin Pharmacol Ther 1997;61:201.